AP# [003]

Related by string. AP# [001] . AP# [002] . AP# [004] * * Westinghouse AP# . Westinghouse AP# reactor . Meru AP# . Westinghouse AP# reactors . AP# PWR . AP# reactors . candidate AP# . AP# reactor . Photo Anonymous AP# . s AP# reactor . Westinghouse AP# TM . AP# pilot . AP# reactor design . candidate oral AP# . Four AP# reactors . MW AP# reactors . AP# Consortium . STEP AP# . Anonymous AP# *

Related by context. Frequent words. (Click for all words.) 72 carfilzomib 71 MGCD# [001] 70 IMGN# 70 T DM1 69 INCB# [002] 69 perifosine 69 Phase Ib 68 XL# [003] 67 pralatrexate 67 PLX# 66 Marqibo 66 brentuximab vedotin 66 CYT# 66 voreloxin 65 MDV# 65 satraplatin 65 tamibarotene 65 FOLOTYN 65 CUDC 65 RDEA# 64 clofarabine 64 HspE7 64 hematological malignancies 64 ASA# 64 RNAi therapeutic 64 Phase 2b trial 64 dasatinib 63 antitumor activity 63 tivozanib 63 picoplatin 63 mipomersen 63 elesclomol 63 ONCONASE 63 Phase 1b 63 Phase 2b 63 ISIS # 63 eculizumab 63 dose escalation 63 Phase IIa clinical 63 kinase inhibitor 63 ADVEXIN 63 taxane 63 solid tumors 62 anticancer agents 62 Satraplatin 62 Phase 2a clinical 62 Actemra 62 APD# 62 cutaneous T cell 62 Alpharadin 62 RG# [001] 62 CBLB# 62 Opexa 62 humanized monoclonal antibody 62 Phase 2a 62 Phase 2b clinical 62 investigational compound 62 Phase III 62 ENMD 62 bavituximab 61 MGCD# [002] 61 Phase 2b study 61 PRX # 61 Genasense 61 FTY# 61 preclinical studies 61 hematologic malignancies 61 Phase IIb trial 61 chemotherapeutic agents 61 Phase III clinical 61 LymphoStat B 61 metastatic melanoma 61 bortezomib 60 chronic lymphocytic leukemia CLL 60 ofatumumab 60 panitumumab 60 kinase inhibitors 60 ZEVALIN 60 nimotuzumab 60 preclinical 60 pivotal Phase III 60 taxanes 60 IDX# 60 daclizumab 60 gefitinib 60 VELCADE 60 NSCLC 59 ambrisentan 59 diabetic nephropathy 59 ALKS 59 relapsing remitting multiple sclerosis 59 gemcitabine 59 disease modifying 59 epratuzumab 59 ARRY 59 CRx 59 ipilimumab 59 AEOL # 59 Phase IIa trial 59 cancer immunotherapy 59 hormone refractory prostate cancer

Back to home page